- Home
- SNES vs QNRX Comparison
SNES vs QNRX Comparison
Compare SNES & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNES | QNRX |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 10.1M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNES | QNRX |
|---|---|---|
| Price | $1.87 | $7.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 47.6K | 34.7K |
| Earning Date | 03-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,301,000.00 | N/A |
| Revenue This Year | $41.52 | N/A |
| Revenue Next Year | $77.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.37 | N/A |
| 52 Week Low | $1.30 | $5.01 |
| 52 Week High | $6.24 | $41.80 |
Technical Indicators
Market Signals| Indicator | SNES | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.45 | 33.58 |
| Support Level | $1.75 | $7.07 |
| Resistance Level | $2.19 | $8.46 |
| Average True Range (ATR) | 0.14 | 0.88 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 17.53 | 19.75 |
Price Performance
Historical ComparisonAbout SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.